The past, present and future of lipid-lowering therapy

2015 ◽  
Vol 10 (6) ◽  
pp. 481-498 ◽  
Author(s):  
Osman Najam ◽  
Gilles Lambert ◽  
Kausik K Ray
Keyword(s):  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
The Past ◽  
Lowering Therapy

scholarly journals Statins as a component of lipid-lowering therapy

2020 ◽  
Vol 17 (4) ◽  
pp. 79-82
Author(s):  
Andrey I. Danilov ◽  
Sergey N. Kozlov ◽  
Andrey V. Evseev
Keyword(s):  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
The Past ◽  
Cholesterol Levels ◽  
Lowering Therapy ◽  
Main Class ◽  
The Russian Federation ◽  
Overall Mortality

Statins are the main class of drugs that are used to treat patients with hyperlipidemia and atherosclerosis. Over the past decades, dozens of randomized clinical trials with this group of drugs have been conducted. Their results showed a significant reduction in cardiovascular and overall mortality, regardless of gender, age, baseline cholesterol levels. Currently, 6 drugs of this class are registered in the Russian Federation: Atorvastatin, Lovastatin, Simvastatin, Pravastatin, Rosuvastatin and Fluvastatin.

scholarly journals Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e045482
Author(s):  
Didier Collard ◽  
Nick S Nurmohamed ◽  
Yannick Kaiser ◽  
Laurens F Reeskamp ◽  
Tom Dormans ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cox Regression ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Cvd Risk Factors ◽  
Cvd Risk ◽  
Icu Admission ◽  
Lowering Therapy ◽  
Secondary Outcomes ◽  
Age And Sex

ObjectivesRecent reports suggest a high prevalence of hypertension and diabetes in COVID-19 patients, but the role of cardiovascular disease (CVD) risk factors in the clinical course of COVID-19 is unknown. We evaluated the time-to-event relationship between hypertension, dyslipidaemia, diabetes and COVID-19 outcomes.DesignWe analysed data from the prospective Dutch CovidPredict cohort, an ongoing prospective study of patients admitted for COVID-19 infection.SettingPatients from eight participating hospitals, including two university hospitals from the CovidPredict cohort were included.ParticipantsAdmitted, adult patients with a positive COVID-19 PCR or high suspicion based on CT-imaging of the thorax. Patients were followed for major outcomes during the hospitalisation. CVD risk factors were established via home medication lists and divided in antihypertensives, lipid-lowering therapy and antidiabetics.Primary and secondary outcomes measuresThe primary outcome was mortality during the first 21 days following admission, secondary outcomes consisted of intensive care unit (ICU) admission and ICU mortality. Kaplan-Meier and Cox regression analyses were used to determine the association with CVD risk factors.ResultsWe included 1604 patients with a mean age of 66±15 of whom 60.5% were men. Antihypertensives, lipid-lowering therapy and antidiabetics were used by 45%, 34.7% and 22.1% of patients. After 21-days of follow-up; 19.2% of the patients had died or were discharged for palliative care. Cox regression analysis after adjustment for age and sex showed that the presence of ≥2 risk factors was associated with increased mortality risk (HR 1.52, 95% CI 1.15 to 2.02), but not with ICU admission. Moreover, the use of ≥2 antidiabetics and ≥2 antihypertensives was associated with mortality independent of age and sex with HRs of, respectively, 2.09 (95% CI 1.55 to 2.80) and 1.46 (95% CI 1.11 to 1.91).ConclusionsThe accumulation of hypertension, dyslipidaemia and diabetes leads to a stepwise increased risk for short-term mortality in hospitalised COVID-19 patients independent of age and sex. Further studies investigating how these risk factors disproportionately affect COVID-19 patients are warranted.

Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study

2013 ◽  
Vol 70 (1) ◽  
pp. 99-108 ◽  
Author(s):  
D. Macías Saint-Gerons ◽  
C. de la Fuente Honrubia ◽  
D. Montero Corominas ◽  
M. J. Gil ◽  
F. de Andrés-Trelles ◽  
...  
Keyword(s):  
Primary Prevention ◽  
Vascular Diseases ◽  
Population Based ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Population Based Study ◽  
Lowering Therapy

LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy

2012 ◽  
Vol 47 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Angelo Zinellu ◽  
Salvatore Sotgia ◽  
Elisabetta Pisanu ◽  
Giacomina Loriga ◽  
Luca Deiana ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy
Sign in / Sign up

Export Citation Format

Share Document